Maternal fructose intake aggravates the harmful effects of a Western diet in rat male descendants impacting their cholesterol metabolism.

Scope: fructose consumption from added sugars correlates with the epidemic rise in MetS and CVD. Maternal fructose intake has been described to program metabolic diseases in progeny. However, consumption of fructose-containing beverages is allowed during gestation. Cholesterol is also a well-known risk factor for CVD. Therefore, it is essential to study Western diets which combine fructose and cholesterol and how maternal fructose can influence the response of progeny to these diets. Methods and results: a high-cholesterol (2%) diet combined with liquid fructose (10%), as a model of an unhealthy Western diet, was administered to descendants from control and fructose-fed mothers. Gene (mRNA and protein) expression and plasma, fecal and tissue parameters of cholesterol metabolism were measured. Interestingly, progeny from fructose-fed dams consumed less liquid fructose and cholesterol-rich chow than males from control mothers. Moreover, descendants of fructose-fed mothers fed a Western diet showed an increased cholesterol elimination through bile and feces than males from control mothers. Despite these mitigating circumstances to develop a proatherogenic profile, the same degree of hypercholesterolemia and severity of steatosis were observed in all descendants fed a Western diet, independently of maternal intake. An increased intestinal absorption of cholesterol, synthesis, esterification, and assembly into lipoprotein found in males from fructose-fed dams consuming a Western diet could be the cause. Moreover, an augmented GLP2 signalling seen in these animals would explain this enhanced lipid absorption. Conclusions: maternal fructose intake, through a fetal programming, makes a Western diet considerably more harmful in their descendants than in the offspring from control mothers.

Risk factors for lymphedema after breast surgery: A prospective cohort study in the era of sentinel lymph node biopsy.

INTRODUCTION: The Objective was to investigate the incidence of lymphedema after breast cancer treatment and to analyze the risk factors involved in a tertiary level hospital. METHODS: Prospective longitudinal observational study over 3 years post-breast surgery. 232 patients undergoing surgery for breast cancer at our institution between September 2013 and February 2018. Sentinel lymph node biopsy (SLNB) or axillary lymphadenectomy (ALND) were mandatory in this cohort. In total, 201 patients met the inclusion criteria and had a median follow-up of 31 months (range, 1-54 months). Lymphedema was diagnosed by circumferential measurements and truncated cone calculations. Patients and tumor characteristics, shoulder range of motion limitation and local and systemic therapies were analyzed as possible risk factors for lymphedema. RESULTS: Most cases of lymphedema appeared in the first 2 years. 13.9% of patients developed lymphedema: 31% after ALND and 4.6% after SLNB (p < 0.01), and 46.7% after mastectomy and 11.3% after breast-conserving surgery (p < 0.01). The lymphedema rate increased when axillary radiotherapy (RT) was added to radical surgery: 4.3% for SLNB alone, 6.7% for SLNB + RT, 17.6% for ALND alone, and 35.2% for ALND + RT (p < 0.01). In the multivariate analysis, the only risk factors associated with the development of lymphedema were ALND and mastectomy, which had hazard ratios (95% confidence intervals) of 7.28 (2.92-18.16) and 3.9 (1.60-9.49) respectively. CONCLUSIONS: The main risk factors for lymphedema were the more radical surgeries (ALND and mastectomy). The risk associated with these procedures appeared to be worsened by the addition of axillary radiotherapy. A follow-up protocol in patients with ALND lasting at least two years, in which special attention is paid to these risk factors, is necessary to guarantee a comprehensive control of lymphedema that provides early detection and treatment.

Prognostic factors at admission on patients with cancer and COVID-19: Analysis of HOPE registry data.

BACKGROUND: Previous works seem to agree in the higher mortality of cancer patients with COVID-19. Identifying potential prognostic factors upon admission could help identify patients with a poor prognosis. METHODS: We aimed to explore the characteristics and evolution of COVID-19 cancer patients admitted to hospital in a multicenter international registry (HOPE COVID-19).Our primary objective is to define those characteristics that allow us to identify cancer patients with a worse prognosis (mortality within 30 days after the diagnosis of COVID-19). RESULTS: 5838 patients have been collected in this registry, of whom 770 had cancer among their antecedents. In hospital mortality reached 258 patients (33.51%). The median was 75 years (65-82). Regarding the distribution by sex, 34.55% of the patients (266/770) were women.The distribution by type of cancer: genitourinary 238/745 (31.95%), digestive 124/745 (16.54%), hematologic 95/745 (12.75%).In multivariate regression analysis, factors that are independently associated with mortality at admission are: renal impairment (OR 3.45, CI 97.5% 1.85-6.58), heart disease (2.32, 1.47-3.66), liver disease (4.69, 1.94-11.62), partial dependence (2.41, 1.34-4.33), total dependence (7.21, 2.60-21.82), fatigue (1.84, 1.16-2.93), arthromialgias (0.45, 0.26-0.78), SatO2 < 92% (4.58, 2.97-7.17), elevated LDH (2.61, 1.51-4.69) and abnormal decreased Blood Pressure (3.57, 1.81-7.15). Analitical parameters are also significant altered. CONCLUSION: In patients with cancer from the HOPE registry, 30-day mortality from any cause is high and is associated with easily identifiable clinical factors upon arrival at the hospital. Identifying these patients can help initiate more intensive treatments from the start and evaluate the prognosis of these patients.

ANTECEDENTES: Trabajos previos parecen coincidir en la mayor mortalidad de los pacientes con cáncer y COVID-19. La identificación de posibles factores pronósticos en el momento del ingreso podría ayudar a identificar a los pacientes con mal pronóstico. MÉTODOS: Nos propusimos explorar las características y la evolución de los pacientes con cáncer y COVID-19 ingresados en un registro internacional multicéntrico (HOPE COVID-19).Nuestro objetivo principal es definir aquellas características que nos permitan identificar a los pacientes con cáncer de peor pronóstico (mortalidad en los 30 días siguientes al diagnóstico de COVID-19). RESULTADOS: En este registro se ha recogido a 5.838 pacientes, de los cuales 770 tenían cáncer entre sus antecedentes. La mortalidad hospitalaria alcanzó a 258 pacientes (33,51%). La mediana fue de 75 años (65-82). En cuanto a la distribución por sexo, el 34,55% de los pacientes eran mujeres (266/770).La distribución por tipo de cáncer: genitourinario 238/745 (31,95%), digestivo 124/745 (16,54%) y hematológico 95/745 (12,75%).En el análisis de regresión multivariante, los factores que se asocian de forma independiente con la mortalidad al ingreso son: insuficiencia renal (OR 3,45; IC 97,5%: 1,85-6,58), cardiopatía (2,32; 1,47-3,66), hepatopatía (4,69; 1,94-11,62), dependencia parcial (2,41; 1,34-4,33), dependencia total (7,21; 2,60-21,82), fatiga (1,84, 1;16-2,93), artromialgias (0,45; 0,26-0,78), SatO2 < 92% (4,58; 2,97-7,17), LDH elevada (2,61; 1,51-4,69) y disminución anormal de la presión arterial (3,57; 1,81-7,15). Los parámetros analíticos también están significativamente alterados. CONCLUSIÓN: En los pacientes con cáncer del registro HOPE, la mortalidad a los 30 días por cualquier causa es elevada y se asocia a factores clínicos fácilmente identificables a su llegada al hospital. La identificación de estos pacientes puede ayudar a iniciar tratamientos más intensivos desde el principio y evaluar el pronóstico de estos pacientes.

Prognostic factors at admission on patients with cancer and COVID-19: Analysis of HOPE registry data.

BACKGROUND: Previous works seem to agree in the higher mortality of cancer patients with COVID-19. Identifying potential prognostic factors upon admission could help identify patients with a poor prognosis. METHODS: We aimed to explore the characteristics and evolution of COVID-19 cancer patients admitted to hospital in a multicenter international registry (HOPE COVID-19). Our primary objective is to define those characteristics that allow us to identify cancer patients with a worse prognosis (mortality within 30 days after the diagnosis of COVID-19). RESULTS: 5838 patients have been collected in this registry, of whom 770 had cancer among their antecedents. In hospital mortality reached 258 patients (33.51%). The median was 75 years (65-82). Regarding the distribution by sex, 34.55% of the patients (266/770) were women. The distribution by type of cancer: genitourinary 238/745 (31.95%), digestive 124/745 (16.54%), hematologic 95/745 (12.75%). In multivariate regression analysis, factors that are independently associated with mortality at admission are: renal impairment (OR 3.45, CI 97.5% 1.85-6.58), heart disease (2.32, 1.47-3.66), liver disease (4.69, 1.94-11.62), partial dependence (2.41, 1.34-4.33), total dependence (7.21, 2.60-21.82), fatigue (1.84, 1.16-2.93), arthromialgias (0.45, 0.26-0.78), SatO2<92% (4.58, 2.97-7.17), elevated LDH (2.61, 1.51-4.69) and abnormal decreased Blood Pressure (3.57, 1.81-7.15). Analitical parameters are also significant altered. CONCLUSION: In patients with cancer from the HOPE registry, 30-day mortality from any cause is high and is associated with easily identifiable clinical factors upon arrival at the hospital. Identifying these patients can help initiate more intensive treatments from the start and evaluate the prognosis of these patients.

Multiparametric optimization of a new high-sensitive and disposable mercury (II) electrochemical sensor.

An electrochemical sensor for mercury (II) determination was developed by modifying the surface of a commercial screen-printed carbon electrode (SPCE) with a polystyrene sulfonate-NiO-carbon nanopowder composite material. Mercury measurements were performed by differential pulse anodic stripping voltammetry (DPASV). Sensor composition and measurement conditions were optimized using a multivariate experiment design. A screening experiment by using a Plackett-Burman design was first performed in order to determine the main contributing factors to the electrochemical response. The most important factors were employed to establish the interactions between different experimental variables and get the best conditions for mercury determination. For this purpose, a five level central composite design and a response surface methodology were used. The optimized method using the developed NiO-PSS-SPCE sensor presents a very low limit of detection of 0.021 µg L(-1) and a linear response over two concentration ranges with two different slopes, from 0.05 to 2.0 µg L(-1) and between 2.0 and 75 µg L(-1). The sensor was successfully applied to mercury determination in water samples.

Relación entre xerostomía y diabetes mellitus: una complicación poco conocida / Relationship between xerostomia and diabetes mellitus: A little known complication

No disponible

Hígado graso no alcohólico en pacientes con sobrepeso y obesidad infantojuvenil / Non-alcoholic fatty liver in children and adolescents with excess weight and obesity

Fundamentos y objetivo: La esteatosis hepática, también denominada hígado graso no alcohólico (HGNA), es la enfermedad hepática más frecuente en niños obesos y está sufriendo un incremento importante en su incidencia debido al aumento de la obesidad infantil. Los objetivos de nuestro trabajo son: estimar la prevalencia de HGNA en niños con sobrepeso y obesidad utilizando el valor de la glutamate pyruvate transaminase (GPT, «transaminasa glutámico-pirúvica») y la ecografía abdominal, así como correlacionar la presencia de HGNA con distintos parámetros antropométricos y bioquímicos. Pacientes y método: Estudio transversal de prevalencia que incluye pacientes con sobrepeso y obesidad, con edades entre 5 y 15 años, reclutados entre 2004-2012. Las variables independientes incluidas fueron: edad, sexo, peso, talla, índice de masa corporal, perímetro de cintura (PC), índice cintura-talla (ICT), insulinemia,Homeostasis model assessment-insulin resistance (HOMA-R), colesterol total, triglicéridos (TG), high density lipoproteins (HDL, «lipoproteínas de alta densidad»), low density lipoproteins (LDL, «lipoproteínas de baja densidad»), glutamic-oxaloacetic transaminase (GOT, «transaminasa glutámico-oxalacética»), GPT y gamma glutamil transpeptidasa (GGT). Resultados: Se seleccionaron 126 pacientes, con una edad media (DE) de 11,94 (3,12) años. El 19,66% presentó elevación patológica de GPT. Treinta y ocho pacientes (30,15%) presentaron esteatosis hepática utilizando la ecografía abdominal. Los valores de insulinemia, HOMA-R y LDL fueron significativamente mayores en pacientes con alteración de GPT (p = 0,015, p = 0,008 y p = 0,002, respectivamente). Los pacientes con HGNA observado en ecografía también mostraron mayores valores de insulinemia, PC, ICT, colesterol total, TG, LDL, GOT, GPT y GGT que los pacientes con ecografía normal, alcanzándose la significación estadística en valor de insulinemia, HOMA, LDL y GPT. Conclusiones: La esteatosis hepática es un trastorno relativamente frecuente en niños y jóvenes con obesidad. Dos de cada 10 niños –utilizando GPT– y 3 de cada 10 –utilizando la ecografía abdominal– la presentan, y el marcador bioquímico que mejor la define es una elevación de la GPT. Es imprescindible y necesaria una modificación en el estilo de vida que incluya la pérdida de peso como medida principal para evitar complicaciones en la vida adulta (AU)

Basis and objective: Hepatic steatosis, also known as non-alcoholic fatty liver (NAFL), is the most frequent liver disease in obese children. Due to an increase in infantile obesity, it is experiencing a significant increment in incidence. Our objetives are: Estimate the prevalence of NAFL in children with excess weight and obesity using the glutamate pyruvate transaminase (GPT) value as a biochemical test and an abdominal ultrasound, and correlate the presence of hepatic steatosis with various anthropometric and biochemical parameters. Patients and method: Cross-sectional prevalence study which includes children with excess weight and obesity between the ages of 5 and 15 years, between the years 2004-2012. The independent variables included were: age, sex, weight, size, body mass index (BMI), waist circumference (WC), waist size index (WSI), insulinemia, Homeostasis model assessment-insulin resistance (HOMA-R), total cholesterol, triglycerides (TG), high density lipoproteins (HDL), low density lipoproteins (LDL), glutamic-oxaloacetic transaminase (GOT), GPT and gamma-glutamyl transpeptidase (GGT). Results: One hundred and twenty-six patients, with an average age of 11.94 (3.12) years were recruited. A percentage of 19.66 of the patients presented elevated GPT pathology. Of the 126 abdominal ultrasounds performed, 38 patients presented hepatic steatosis (30.15%). The levels of insulinemia, HOMA-R and LDL were significantly higher in patients with altered GPT, compared to those with normal GPT values (P = .015, P = .008 and P = .002, respectively). The patients with an objective HGNA in ultrasound, also showed greater levels of insulinemia, WC, WSI, total cholesterol, TG, LDL, GLT, GPT and GGT than the patients with normal ultrasounds, thereby achieving statistical significance in insulinemia, HOMA-R, LDL and GPT values. Conclusions: NAFL is a relatively frequent disorder in obese children and adolescents. In our study, 2 of 10 children –using GPT– and 3 of every 10 –using abdominal ultrasound– present the same. The biochemical marker which best defines it is an elevation in GPT. A modification in lifestyle which includes weight loss as a principal means of avoiding complications in adult life, is essential and necessary (AU)

[Non-alcoholic fatty liver in children and adolescents with excess weight and obesity]. / Hígado graso no alcohólico en pacientes con sobrepeso y obesidad infantojuvenil.

BASIS AND OBJECTIVE: Hepatic steatosis, also known as non-alcoholic fatty liver (NAFL), is the most frequent liver disease in obese children. Due to an increase in infantile obesity, it is experiencing a significant increment in incidence. Our objetives are: Estimate the prevalence of NAFL in children with excess weight and obesity using the glutamate pyruvate transaminase (GPT) value as a biochemical test and an abdominal ultrasound, and correlate the presence of hepatic steatosis with various anthropometric and biochemical parameters. PATIENTS AND METHOD: Cross-sectional prevalence study which includes children with excess weight and obesity between the ages of 5 and 15 years, between the years 2004-2012. The independent variables included were: age, sex, weight, size, body mass index (BMI), waist circumference (WC), waist size index (WSI), insulinemia, Homeostasis model assessment-insulin resistance (HOMA-R), total cholesterol, triglycerides (TG), high density lipoproteins (HDL), low density lipoproteins (LDL), glutamic-oxaloacetic transaminase (GOT), GPT and gamma-glutamyl transpeptidase (GGT). RESULTS: One hundred and twenty-six patients, with an average age of 11.94 (3.12) years were recruited. A percentage of 19.66 of the patients presented elevated GPT pathology. Of the 126 abdominal ultrasounds performed, 38 patients presented hepatic steatosis (30.15%). The levels of insulinemia, HOMA-R and LDL were significantly higher in patients with altered GPT, compared to those with normal GPT values (P=.015, P=.008 and P=.002, respectively). The patients with an objective HGNA in ultrasound, also showed greater levels of insulinemia, WC, WSI, total cholesterol, TG, LDL, GLT, GPT and GGT than the patients with normal ultrasounds, thereby achieving statistical significance in insulinemia, HOMA-R, LDL and GPT values. CONCLUSIONS: NAFL is a relatively frequent disorder in obese children and adolescents. In our study, 2 of 10 children -using GPT- and 3 of every 10 -using abdominal ultrasound- present the same. The biochemical marker which best defines it is an elevation in GPT. A modification in lifestyle which includes weight loss as a principal means of avoiding complications in adult life, is essential and necessary.

¿Se sustentan las Guías GES en trabajos científicos financiados por los fondos de CONICYT? / Contribution of Chilean research to the formulation of national clinical guidelines

Background: In Chile, 80 diseases were included in a health care system called Health Care Guarantees (GES) and clinical guidelines were elaborated for their management. Aim: To assess the scientific background of guidelines and if they were based on research financed by the Chilean National Commission for Science and Technology. Material and Methods: The references of the 82 guidelines developed for 80 diseases were reviewed, registering their number, authors, country of origin and funding source. Results: The guidelines had a total of 6,604 references. Of these, only 185 were Chilean (2.8%) and five (0.08%) originated from research financed by the National Commission for Science and Technology. Conclusions: The contribution of research funded by national agencies to the formulation of clinical guidelines is minimal.

Calidad de las espirometrías en atención primaria de Tenerife / Quality of spirometry in primary care in Tenerife, Spain

FUNDAMENTO: la espirometría es una prueba no invasiva y objetiva que mide la limitación del flujo aéreo y su técnica requiere unas condiciones que garanticen su calidad para que los resultados tengan valor clínico. OBJETIVOS: el objetivo de este estudio ha sido evaluar la calidad de las espirometrías realizadas en los Centros de Atención Primaria del Área de Salud de Tenerife. MÉTODOS: se realizó un estudio epidemiológico descriptivo para valorar la aceptabilidad y reproducibilidad de las espirometrías. RESULTADOS: el 45,7% de las espirometrías no se consideraron aceptables por el incumplimiento de alguno de los criterios de aceptabilidad. El error más habitual es la presencia de artefactos en la curva. De las espirometrías que reúnen todos los criterios de aceptabilidad, son reproducibles para FVC el 65,6%, para FEV1 el 91% y para FVC + FEV1 el 65,6%.CONCLUSIONES: existió un bajo número de espirometrías que cumplían los criterios de aceptabilidad y reproducibilidad, por lo que es necesaria la mejora de la calidad, con la presencia de personal fijo y bien formado que realice e intérprete estas pruebas de capacidad pulmonar

INTRODUCTION: spirometry is a non-invasive and objective assay that measures airflow limitation. This technique requires certain conditions in order to ensure its quality, so that results are of clinical value. The aim of the study was to analyze the quality of spirometry in primary health care centers in Tenerife, Spain. METHODS: a descriptive epidemiological study was designed in order to assess the reproducibility and acceptability of spirometries. RESULTS: 45,7 % of spirometries were considered non acceptable by unfulfilment of any of the acceptability criteria. Spirometries that met all the acceptability criteria were reproducible for FVC in 65,5% of cases, 91% for FEV1 and 65,6% for FVC and EV1. CONCLUSIONS: there is a low number of spirometries that meet acceptability and reproducibility criteria, thus it is make necessary to improve the quality of this test by the presence of fixed and trained personnel capable of performing and analyzing lung capacity tests

[The X of dyslipemias]. / La X de las dislipemias.

Patients with cholestatic diseases can present secondary hypercholesterolemia, as a result of the accumulation of lipoprotein X (Lp-X); an abnormal LDL form, considered as the biochemical parameter more sensitive and specific for the diagnosis of cholestasis intra or extrahepatic cholestasis. The aim of this clinical communication is to illustrate this association. A 54-year-old male with severe cholestatic liver disease which in turn presents a progressive total cholesterol rise and LDL with presence of lipoprotein X. Total and LDL cholesterol were down to normal, also coinciding with the improvement of cholestatic liver disease conferring cardiovascular protection pattern.

Los pacientes con colestasis hepática pueden presentar hipercolesterolemia secundaria, como consecuencia de la acumulación de la lipoproteína X (Lp-X); una forma anómala de LDL, considerada como el parámetro bioquímico más sensible y específico para el diagnóstico de colestasis intra o extrahepática. El objetivo de esta comunicación clínica es ilustrar esta asociación. Se trata de un varón de 54 años con hepatopatía colestásica severa que a su vez presenta una elevación progresiva de colesterol total y LDL con presencia de lipoproteína X. El colesterol total y LDL, descendieron progresivamente hasta normalizarse, coincidiendo con la mejoría de la función hepática, confiriendo un patrón de protección cardiovascular.

La X de las dislipemias / The "x" of dyslipemias

Los pacientes con colestasis hepática pueden presentar hipercolesterolemia secundaria, como consecuencia de la acumulación de la lipoproteína X (Lp-X); una forma anómala de LDL, considerada como el parámetro bioquímico más sensible y específico para el diagnóstico de colestasis intra o extrahepática. El objetivo de esta comunicación clínica es ilustrar esta asociación. Se trata de un varón de 54 años con hepatopatía colestásica severa que a su vez presenta una elevación progresiva de colesterol total y LDL con presencia de lipoproteína X. El colesterol total y LDL, descendieron progresivamente hasta normalizarse, coincidiendo con la mejoría de la función hepática, confiriendo un patrón de protección cardiovascular (AU)

Patients with cholestatic diseases can present secondary hypercholesterolemia, as a result of the accumulation of lipoprotein X (Lp-X); an abnormal LDL form, considered as the biochemical parameter more sensitive and specific for the diagnosis of cholestasis intra or extrahepatic cholestasis. The aim of this clinical comunication is to illustrate this association. A 54-year-old male with severe cholestatic liver disease wich in turn presents a progressive total cholesterol rise and LDL with presence of lipoprotein X. Total and LDL cholesterol were down to normal, also coinciding with the improvement of cholestatic liver disease conferring cardiovascular protection pattern (AU)

Utilización de la espirometría diagnóstica en los centros de salud de Tenerife / Use of Diagnostic Spirometry in Tenerife Health Centers

Objetivo: determinar el uso de la espirometría diagnóstica en el Área de Salud de Tenerife y la disponibilidad de medios materiales y humanos para su realización. Método: se efectuó un estudio descriptivo transversal en el periodo de marzo a junio de 2011, en el Área de Salud de Tenerife, que abarca toda la isla, en el que se incluyeron los 38 centros de salud del área. La recogida de datos se llevó a cabo mediante un cuestionario elaborado y administrado por el equipo investigador, basado en el publicado por Naveran et al (1994) y que consta de 18 preguntas sobre la utilización de la espirometria. Los entrevistados fueron los profesionales encargados de la realización de las pruebas y los responsables de la subdirección del centro, en caso de que no se realizase esta técnica. Resultados: se cumplimentaron los cuestionarios de los 38 centros (100%).El 89,4% de los centros de salud disponen de espirómetro; realizan espirometrías el 71%; en el 85% de los centros las espirometrías las efectúa enfermeras/os; el 96% de las cuales ha recibido una formación básica sobre la utilización de esta técnica; se calibra el espirómetro y se limpia y desinfecta cada vez que se utiliza en el 84,6% de los centros; la media de espirometrías a la semana por centro es de siete y el tiempo medio de espera es de 36 días Conclusiones: aunque es alto el porcentaje de centros de salud que realizan la espirometría, la mejora de la formación enfermera y de los ratios enfermera/médico podría incrementar la media de pruebas semanales y hacerla más accesible a la población (AU)

Objective: to determine the use of Diagnostic Spirometry in the Tenerife Healthcare Area, and the availability of material and human resources in order to perform it. Method: a transversal descriptive study was conducted from March to June, 2011, in the Tenerife Healthcare Area, including the whole island and the 38 health centers in the area. Data collection was conducted through a questionnaire prepared and administered by the research team, based on the one published by Naveran et al (1994), consisting of 18 questions about the use of spirometry. The respondents were the healthcare professionals responsible for conducting tests, and the Healthcare Center Section Managers, in those centers where the test was not conducted. Results: the questionnaires were completed in all 38 centers (100%).There is a spirometer in 89.4% of health centers; spirometries are conducted in 71% of health centers; spirometries are performed by nurses in 85% of health centers; 96% of said nurses have received basic training on the use of this technique; the spirometer is readjusted, cleaned and disinfected after each use in 84.6% of health centers; the average number of spirometries per week is seven, and the average time of wait is of 36 days. Conclusions: even though the proportion of health centers performing spirometry is high, an improvement in nurse training and nursephysician ratio could increase the average number of weekly tests, so that it became more accessible to the population (AU)

Características clínicas de los pacientes con amiloidosis sistémicas en el periodo 2000 - 2010 / Clinical characteristics of the patients with systemic amyloidosis in 2000-2010

Antecedentes. La epidemiología de las amiloidosis sistémicas está cambiando en las últimas décadas. Describimos las características clínicas de los pacientes con amiloidosis sistémicas atendidos en nuestro centro en el periodo 2000-2010 y las comparamos con las anteriores series españolas. Pacientes y métodos. Estudio observacional retrospectivo de pacientes con diagnóstico de amiloidosis sistémica en un hospital terciario entre enero de 2000 y diciembre de 2010. Se excluyó a los pacientes sin diagnóstico histológico y a aquellos con formas asociada a diálisis, seniles o localizadas. Mediante revisión sistemática de las historias clínicas se recogieron las variables demográficas, clínicas, de diagnóstico, seguimiento y mortalidad. Resultados. Se estudió a 55 pacientes, 24 (44%) tenían amiloidosis AL, 30 (56%), amiloidosis AA y un paciente, una forma familiar. Las enfermedades inflamatorias subyacentes más frecuentes fueron la artritis reumatoide (9 pacientes, 30%) y la espondilitis anquilosante (4 enfermos, 13%). El órgano más frecuentemente afectado fue el riñón (36 pacientes, 67%), con una proteinuria al diagnóstico de 3,4±3,7g/24h. El tiempo hasta el diagnóstico fue de 3 meses (rango intercuartílico [RIC]:1-17). La mediana de seguimiento fue de 24 meses (RIC:10-94). Durante el seguimiento fallecieron 31 pacientes y 18 muertes fueron atribuíbles a la amiloidosis. Conclusiones. La afectación renal es la presentación más prevalente de las amiloidosis sistémicas, sin cambios en las últimas décadas. Observamos un largo tiempo de latencia hasta el diagnóstico, por lo que es preciso mantener un alto grado de sospecha clínica de estos procesos(AU)

Background. The epidemiology of systemic amyloidosis has been changing in the last decades. We aim to describe the clinical characteristics of the patients seen at our institution with systemic amyloidosis in 2000-2010 and compare them with previous Spanish series. Patients and methods. An observational, retrospective study was performed on all patients admitted to a tertiary hospital in Madrid, Spain who had been diagnosed of amyloidosis from January 2000 to December 2010. Patients without a proven diagnosis of amyloidosis, with dialysis-associated, senile, or localized forms of amyloidosis were excluded from the study. A systematic review was made of the clinical records, collecting the demographic, clinical and biochemical variables at diagnosis and patients’ outcome. Results. A total of 55 patients were studied, 24 (44%) of whom had AL amyloidosis, 30 (56%) AA amyloidosis, and 1 a familiar form. The most frequent underlying disorders were rheumatoid arthritis (9 patients, 30%) and ankylosing spondylitis (4 cases, 13%). The kidneys were the most frequently involved organ (36 patients, 67%) with nephrotic-range proteinuria at diagnosis (3.4±3.7g/24h). Median time to diagnosis was 3 months (interquartile range [IQR]: 1-17). Median follow-up time was 24 months (IQR: 10-91). During follow-up 31 patients died; 18 of those deaths were related to amyloidosis. Conclusions. Renal dysfunction dominates the course of systemic amyloidosis, which does not seem to have changed in the last decades. We have observed an important delay in the diagnosis of these processes. Therefore, it is necessary to maintain a high degree of clinical suspicion regarding these conditions(AU)

Paracoccidioidomicose: caso clínico / Paracoccidioidiomycosis: case report

Os autores reportam o caso clínico de um homem, 43 anos de idade, natural e residente na ilha da Madeira, emigrado na Venezuela até há 6 anos. Em Março 2009, observado por aparecimento de lesão pápulo-crostosa de bordos regulares eritematosos, indolor, pruriginosa, com dimensões de 4,5 x 3cm, localizada no dorso, com 2 meses de evolução. Como antecedentes, refere história de lesão da mucosa bucal, com exame histopatológico compatível com paracoccidioidomicose (PCM). Foram efectuadas duas biópsias da lesão cutânea para avaliação histopatológica e micológica. O exame histopatológico revelou a presença de múltiplas células circulares, sugerindo distribuição característica de "roda de leme". O estudo micológicos revelou,no exame directo, a presença de leveduras - algumas em gemulação. As culturas permitiram isolar o Paracoccidioides brasiliensis. A radiografia pulmonar apresentava infiltrado bilateral e simétrico, nos lobos centrais e basais. A Tomografia Axial Computadorizada torácica demonstrou múltiplosnódulos espiculados, áreas de opacidade e bronquiectasias.Foi efectuada broncofibroscopia (sem alterações) e simultaneamente foi obtido o lavado broncoalveolar (LBA). A cultura, a 25º C, revelou a presença de hifas e clamidósporos (forma filamentosa). Na cultura, a 37º C, não se obteve a forma leveduriforme.O tratamento efectuado foi o itraconazol 200 mg/dia, durante 6 meses, com regressão da lesão.Até à actualidade, nenhum caso de PCM foi reportado na ilha da Madeira, Portugal. Embora não seja frequente, fora das áreas endémicas, os dermatologistas devem ser capazes de reconhecer e diagnosticar micoses sistémicas, como a PCM (AU)

We report a case of a 43 years-old portuguese man, natural and resident in Madeira island, who was emigrated in Venezuela until 6 years ago. He was observed on March 2008 for a crusted papulo-nodular lesion with erythematous regular borders, pruritic and sized 4,5 x 3,0 cm, located on the dorsum, with a 2 month history. There was no palpable lymphadenopathy. He denied other simptomatology. On March of 1999, the patient had a mouthlesion which was compatible with paracoccidioidomycosis on histopathological examination. He was not aware of any associated pathologies. We performed two punch biopsies of the cutaneous lesion for histopathological and mycological examination. The histopathology showed the presence of multiple round cells of different size (yeast cells) in a narrow base suggesting the classic “pilot’s wheels”, on Hematoxiline & Eosine stain. On direct microscopic examination the mycology revealed yeast of different sizes - some of them on gemulation. The cultures, at 24º and 37º, isolated Paracoccidioides brasiliensis. The thoracic x-ray revealed a heterogeneous, bilateral and symmetric pattern located towards the central and basal portions. The CT scan of the chest showed multiple, micronodular and striated lesions (some of them with small cavities), with tendency to coalesce. To characterize better these lung abnormalities, the patient performed a fibrobronchoscopy of the respiratory tract which was normal. The culture, at 25 ºC, obtained from the sputum of the bronchoalveolar lavage fluid (BAL) showed Paracoccidioides brasiliensis. Routine laboratory studies were normal and serology negative for HIV and tuberculosis. The treatment of choice was itraconazol 200 mg/day, for 6months. As far as we know no case of PCM has been reported in Madeira. Although it is not a frequent disease outside the endemic areas, dermatologists should be able to recognise and diagnose systemic mycosis like PCM (AU)

Clinical characteristics of the patients with systemic amyloidosis in 2000-2010.

BACKGROUND: The epidemiology of systemic amyloidosis has been changing in the last decades. We aim to describe the clinical characteristics of the patients seen at our institution with systemic amyloidosis in 2000-2010 and compare them with previous Spanish series. PATIENTS AND METHODS: An observational, retrospective study was performed on all patients admitted to a tertiary hospital in Madrid, Spain who had been diagnosed of amyloidosis from January 2000 to December 2010. Patients without a proven diagnosis of amyloidosis, with dialysis-associated, senile, or localized forms of amyloidosis were excluded from the study. A systematic review was made of the clinical records, collecting the demographic, clinical and biochemical variables at diagnosis and patients' outcome. RESULTS: A total of 55 patients were studied, 24 (44%) of whom had AL amyloidosis, 30 (56%) AA amyloidosis, and 1 a familiar form. The most frequent underlying disorders were rheumatoid arthritis (9 patients, 30%) and ankylosing spondylitis (4 cases, 13%). The kidneys were the most frequently involved organ (36 patients, 67%) with nephrotic-range proteinuria at diagnosis (3.4 ± 3.7 g/24 h). Median time to diagnosis was 3 months (interquartile range [IQR]: 1-17). Median follow-up time was 24 months (IQR: 10-91). During follow-up 31 patients died; 18 of those deaths were related to amyloidosis. CONCLUSIONS: Renal dysfunction dominates the course of systemic amyloidosis, which does not seem to have changed in the last decades. We have observed an important delay in the diagnosis of these processes. Therefore, it is necessary to maintain a high degree of clinical suspicion regarding these conditions.

Hyperuricemia and metabolic syndrome in children with overweight and obesity

Objetivo: Estudiar la prevalencia de hiperuricemia en niños con sobrepeso u obesidad y analizarla relación con el síndrome metabólico y las enfermedades que lo definen. Materiales y métodos: Se realizó un estudio de prevalencia transversal en 148 niños con sobrepeso u obesidad (12 ± 3 años, 48% chicos, IMC 31,8 ± 6,1) reclutados de una consulta de endocrinología pediátrica. Se determinaron el IMC, la cintura-talla, el perímetro de la cintura, la presión arterial con el equipo habitual y la glucosa (en ayunas y tras sobrecarga con 75 g), la resistencia a la insulina, el colesterol HDL, los triglicéridos y el ácido úrico. Resultados: La prevalencia de hiperuricemia era del 53%. Los pacientes con hiperuricemia tenían valores superiores de IMC (33,9 frente a 30,6; p = 0,003), perímetro de cintura (101,4frente a 91,1 cm; p < 0,001) y presión arterial sistólica (123,4 frente a 111,9 mmHg; p < 0,001)y diastólica (78,2 frente a 68,7 mmHg; p < 0,001). Mostraban además una glucemia más alta después de la sobrecarga oral de glucosa (107,5 frente a 100,7 mg/dl; p = 0,03), valores superiores de insulina (29,2 frente a 20,7 mg/dl; p = 0,001) y HOMA IR (6,5 frente a 4,4; p < 0,001) y concentraciones más bajas de HDL (49,5 frente a 54,4 mg/dl; p = 0,02).El valor de ácido úrico correspondiente con mayor probabilidad al diagnóstico de síndrome metabólico en nuestra muestra era de 5,4 mg/dl (sensibilidad del 64% y especificidad del 62%).Conclusión: La prevalencia de hiperuricemia en niños con sobrepeso y obesidad es alta. En el grupo de pacientes con obesidad e hiperuricemia hallamos que los parámetros determinados para diagnosticar el síndrome metabólico eran menos favorables. La concentración de ácido úrico a partir de la cual existe una mayor posibilidad de encontrar síndrome metabólico es de5,4 mg/dl (AU)

Objective: To study the prevalence of hyperuricemia in children with overweight or obesity and analyze the relation with metabolic syndrome and the diseases that define it. Materials and methods This is a cross-sectional prevalence study in 148 children recruited from pediatric endocrinology consultation, with overweight or obesity (12±3 years, 48% boys, BMI 31.8±6.1). We measured BMI, waist-height, waist circumference, blood pressure with standard instrumentation and glucose (fasting and after overload with 75g), insulin resistance, cholesterol HDL, triglycerides and uric acid. Results The prevalence of hyperuricemia was 53%. Patients with hyperuricemia had greater BMI (33.9 vs 30.6, p=0.003), plus waist circumference (101.4 vs 91.1cm, p<0.001), higher blood pressure: systolic (123.4 vs 111.9mm Hg, p<0.001), diastolic (78.2 vs 68.7mm Hg, p<0.001). They presented greater blood glucose after overload oral glucose (107.5 vs 100.7mg/dl, p=0.03), insulin was higher (29.2 vs 20.7mg/dl, p=0.001) as well as HOMA IR (6.5 vs 4.4, p<0.001) and HDL levels were lower (49.5 vs 54.4mg/dl, p=0.02).Uric acid's level which most is the likely diagnosis of metabolic syndrome corresponds to 5.4mg/dl in our sample (sensitivity: 64% and specificity 62%).Conclusion The prevalence of hyperuricemia in children with overweight and obesity is high. In the group of patients with obesity and hyperuricemia, we found out that the parameters measured to diagnose with metabolic syndrome were less favorable. Uric acid's level from where there is a higher possibility to see metabolic syndrome is 5.4mg/dl (AU)

Hyperuricemia and metabolic syndrome in children with overweight and obesity.

OBJECTIVE: To study the prevalence of hyperuricemia in children with overweight or obesity and analyze the relation with metabolic syndrome and the diseases that define it. MATERIALS AND METHODS: This is a cross-sectional prevalence study in 148 children recruited from pediatric endocrinology consultation, with overweight or obesity (12±3 years, 48% boys, BMI 31.8±6.1). We measured BMI, waist-height, waist circumference, blood pressure with standard instrumentation and glucose (fasting and after overload with 75 g), insulin resistance, cholesterol HDL, triglycerides and uric acid. RESULTS: The prevalence of hyperuricemia was 53%. Patients with hyperuricemia had greater BMI (33.9 vs 30.6, p=0.003), plus waist circumference (101.4 vs 91.1cm, p<0.001), higher blood pressure: systolic (123.4 vs 111.9 mm Hg, p<0.001), diastolic (78.2 vs 68.7 mm Hg, p<0.001). They presented greater blood glucose after overload oral glucose (107.5 vs 100.7 mg/dl, p=0.03), insulin was higher (29.2 vs 20.7 mg/dl, p=0.001) as well as HOMA IR (6.5 vs 4.4, p<0.001) and HDL levels were lower (49.5 vs 54.4 mg/dl, p=0.02). Uric acid's level which most is the likely diagnosis of metabolic syndrome corresponds to 5.4 mg/dl in our sample (sensitivity: 64% and specificity 62%). CONCLUSION: The prevalence of hyperuricemia in children with overweight and obesity is high. In the group of patients with obesity and hyperuricemia, we found out that the parameters measured to diagnose with metabolic syndrome were less favorable. Uric acid's level from where there is a higher possibility to see metabolic syndrome is 5.4 mg/dl.